The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

Blood Cancer Journal

Volumn 5, Issue , 2015, Pages e352-

  Diaz Beya M ^a,b   Brunet, S ^b,c   Nomdedeu J ^b,c   Cordeiro, A ^d   Tormo, M ^e   Escoda, L ^f   Ribera, J M ^b,g   Arnan, M ^h   Heras, I ⁱ   Gallardo, D ^j   Bargay, J ^k   Queipo De Llano, M P ^l   Salamero, O ^m   Marti J M ⁿ   Sampol, A ^k   Pedro, C ^o   Hoyos, M ^c   Pratcorona, M ^a,b   Castellano, J J ^d   Nomdedeu, M ^a,b   Risueno R M ^b   Sierra, J ^b,c   Monzo M ^d   Navarro, A ^d   Esteve, J ^a,b,d   more..

^a HOSPITAL CLÍNIC   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL DURAN I REYNALS   (Spain)

ⁱ HOSPITAL MORALES MESEGUER   (Spain)

^j Hematology Department ICO Josep Trueta   (Spain)

^k HOSPITAL SON LLÀTZER   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL MÚTUA DE TERRASSA   (Spain)

^o HOSPITAL DEL MAR   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MICRORNA; MICRORNA 3151; MITOXANTRONE; UNCLASSIFIED DRUG; BAALC PROTEIN, HUMAN; MIRN3151 MICRORNA, HUMAN; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CYTOGENETICS; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HUMAN; INTERMEDIATE RISK PATIENT; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; ACUTE MYELOID LEUKEMIA; ADOLESCENT; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84943169416     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.76     Document Type: Article

References (35)

1. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
4. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918.
5. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010; 10: 23-36.
6. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-6418.
7. Schotte D, Pieters R, Den Boer M. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2011; 26: 1-12.
8. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008; 3: e2141.
9. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111: 5078-5085.
10. Diaz-Beya M, Navarro A, Ferrer G, Diaz T, Gel B, Camos M et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 2012; 27: 595-603.
11. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
12. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945-3950.
13. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928.
14. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008; 26: 5078-5087.
15. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
16. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia 2012; 27: 100-106.
17. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
18. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu Y-Z, Mrózek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086-2093.
19. Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M et al. Micro-RNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia 2014; 28: 804-812.
20. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC et al. Characterization of the melanoma miRNAome by deep sequencing. PLoS One 2010; 5: e9685.
21. Schotte D, Akbari Moqadam F, Lange-Turenhout EA, Chen C, van Ijcken WF, Pieters R et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011; 25: 1389-1399.
22. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120: 249-258.
23. Eisfeld A-K, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ et al. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 Pathway. Sci Signal 2014; 7: ra36.
24. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
25. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618-3620.
26. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633.
27. Navarro A, Marrades RM, Vinolas N, Quera A, Agusti C, Huerta A et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009; 76: 162-169.
28. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
30. Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120: 249-258.
31. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
32. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-866.
33. Rücker F, Russ A, Cocciardi S, Kett H, Schlenk R, Botzenhardt U et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 2012; 27: 353-361.
34. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089.
35. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111: 5371-5379.